Efficacy Of Mirtazapine In Stimulant Associated Insomnia In Patients With Adhd

gle-blind placebo lead-in, patients were randomized to five weeks of double-blind treatment. 2 patients discontinued prior to the initial assessment and 38 patients completed at least one week of treatment with risperidone (N 5 19) or placebo (N 5 19). The Positive and Negative Syndrome Scale (PANSS) was the primary outcome measure. Secondary measures included the Clinician Administered PTSD Scale (CAPS) and other assessments. Analysis of end-point measures showed a significant reduction in global psychosis (PANSS ratings) in the risperidone-treated patients but not in the placebo group (p , 0.05). Hallucinations and delusions declined significantly only in the risperidone group. The risperidone group also had a significant reduction in CAPS reexperiencing symptom subscale scores. The average dose of risperidone was 2.5 6 1.7 mg. There were minimal extrapyramidal symptoms in either group. These data support the potential efficacy of risperidone in treating psychotic features associated with PTSD and suggest that core PTSD reexperiencing symptoms may also be responsive.